Bloomage BioTechnology Corporation Limited Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for Bloomage BioTechnology Corporation Limited (SHSE:688363), which a week ago released some disappointing yearly results that could have a notable impact on how t
Huaxi Biotech (688363): Q1 performance improved markedly, medical and aesthetic business continued to grow
Core view: Incident: The company released an annual report and a quarterly report. In 2023, it achieved revenue of 6.076 billion yuan, a year-on-year decrease of 4.45%; net profit to mother was 593 million yuan, down 38.97% year on year; net profit after deducting net profit
Huaxi Biotech (688363): The inflection point in profitability in the first quarter showed leading growth in the medical terminal business
Revenue growth was steady in the first quarter of 2024, and net profit to mother increased 21%. The company's revenue in 2023 was 6.076 billion yuan, -4.45% year-on-year, and net profit to mother was 593 million yuan, or -38.97% year-on-year.
Huaxi Biotech (688363): Q1 surpassed expectations, high medical and aesthetic growth and significant cost reduction
Guide to this report: The company's performance in 2023 was under pressure. The 24Q1 improvement was obvious, and profit recovery exceeded expectations. The main reason was that high growth in medicine and beauty led to structural optimization of profit margins. At the same time, the medical, aesthetic and skincare sector had remarkable cost control results. Focus on subsequent skincare sector revenue
Huaxi Biotech (688363) 2023 Annual Report and 2024 Quarterly Report Review: Accelerated growth in the raw materials and medical terminal business is expected to reach an inflection point after adjustments to the skincare business
Incident: Huaxi Biotech revealed its results for the first quarter of 2023 and 2024. In '23, the company achieved revenue of 6.076 billion yuan, -4.45% year on year; net profit to mother was 593 million yuan, or -38.97% year on year;
Huaxi Biotech (688363): 24Q1 performance gradually improved, looking forward to the results of the company's strategic adjustments
Investment highlights Results for the 2023 adjustment period are under pressure, and 2024Q1 recovery is increasing. In 2023, the company achieved revenue of 6.08 billion yuan (-4.45% year-on-year, same below) and net profit of 590 million yuan (-39.0%) to mother
Huaxi Biotech (688363): Profit picked up in 2024Q1, looking forward to the completion of the company's transformation and revitalization
Incident: In the context of business adjustments in 2023, the 2024Q1 profit side picked up, and the company released an annual report and a quarterly report: achieved revenue of 6.076 billion yuan in 2023 (-4.5% year-on-year, same below) and net return to mother
Huaxi Biology (688363): First seen the dawn in 1Q24 in 24 years or gradually recovered
1Q24 is beginning to see the light of day. I am optimistic about a gradual recovery in 24, with a target price of 80.41 yuan to maintain the “purchase” of Huaxi Biotech's 2023 revenue/net profit attributable to mother/ net profit deducted from non-mother of 60.8/59/49 million
Huaxi Biotech (688363): 24Q1 profit growth exceeded expectations, profit is expected to continue to recover
Event: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 6.076 billion yuan (-4.45%) and net profit to mother of 593 million yuan (-38.97%),
Huaxi Biotech (688363): Continued adjustment of skincare products, medical and aesthetic performance picked up markedly in Q1
Incident: Huaxi Biotech released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 6.076 billion yuan/ -4.45%, net profit to mother of 593 million yuan/ -38.97%, after deducting net income from mother
Huaxi Biotech (688363): The adjustments are showing initial results, but the recovery in performance needs to be further confirmed
In the context of functional skincare business adjustments, Huaxi Biotech's 2023 revenue recorded its first negative growth since launch (-4.5%), and the net profit margin fell to 9.8%, which is basically in line with the 2023 performance report. We are delighted
Express News | Huaxi Biotech: Net profit of 243 million yuan in the first quarter increased 21.39% year-on-year
Why Investors Shouldn't Be Surprised By Bloomage BioTechnology Corporation Limited's (SHSE:688363) P/E
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 29x, you may consider Bloomage BioTechnology Corporation Limited (SHSE:688363) as a stock to avoid entirely w
Huaxi Biotech's “influencer” transformation or what is a custom synthetic creature in the shell
“Investor Network” Cai Jun is standing in the midst of ups and downs, and Huaxi Biotech (688363.SH, hereinafter referred to as the “Company”) is probably still in the rain. In April of this year, the company announced the departure of Ma Shouwei, the former core technician. According to data, Ma Shouwei was previously the functional skincare development director at the Shanghai R&D Center, where he was mainly responsible for basic formulation technology and functional product formulation research and development. Prior to joining the company, he had experience with international brands such as Unilever and L'Oréal. Ma Shouwei's research and development field is mainly cosmetics. This is in line with the company's efforts over the past few years, which is to transform from hyaluronic acid raw materials to a cosmetics company. However, the company said goodbye in 2023
Huaxi Biotech (688363.SH): spent 204 million yuan to repurchase a total of 3.0402 million shares
Gelonghui, April 1, 丨 Huaxi Biotech (688363.SH) announced that as of March 31, 2024, the company had repurchased a total of 3,0402 million shares through the Shanghai Stock Exchange trading system, accounting for 0.6312% of the company's total share capital. The highest price of the repurchase transaction was 89.71 yuan/share, the lowest price was 56.90 yuan/share, and the total amount of capital paid was RMB 204 million (excluding transaction fees such as stamp duty and transaction fees).
Express News | Huaxi Biotech invests in the establishment of a management consulting company with businesses related to artificial intelligence
Express News | Huaxi Biotech Beijing invests in the establishment of a new company including health food sales business
Bloomage BioTechnology Corporation Limited's (SHSE:688363) Last Week's 3.6% Decline Must Have Disappointed Private Equity Firms Who Have a Significant Stake
Key Insights Bloomage BioTechnology's significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public The largest shareholder of the
Huaxi Biotech (688363.SH): A total of 2.71 million shares were repurchased at a cost of 183 million yuan
Gelonghui, March 5, 丨 Huaxi Biotech (688363.SH) announced that as of February 29, 2024, the company had repurchased 2.71 million shares of the company's shares through centralized bidding transactions, accounting for 0.5626% of the company's total share capital of 481,678,242 shares. The highest price of the repurchase transaction was 89.71 yuan/share, the lowest price was 56.90 yuan/share, and the total amount of capital paid was RMB 183 million (excluding transaction fees such as stamp duty and transaction fees).
*ST Beauty Valley (000615.SZ): Some medical and aesthetic consumables are Huaxi Biotech products
Gelonghui March 5 | An investor asked *ST Meigu (000615.SZ) on the investor interactive platform, “How are your company's cooperation discussions with Huaxi Biotech?” The company replied that some of the company's medical and aesthetic consumables are Huaxi Biotech products.
No Data